A021806
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Principal Investigator(s): Kevin Wood, MD
Status: Open and enrolling
Clinical Trials
To view the clinical trials Valley currently has available, please use the search field or select a clinical specialty from the drop-down list below. Be sure to check back frequently, as we are always adding new studies.
For more information about any of our clinical trials, please email [email protected] or call 201-447-8453. (For cancer clinical trials, please call 201-634-5792.)
A021806
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer.
Principal Investigator(s): Kevin Wood, MD
Status: Open and enrolling
A081801 Alchemist
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Principal Investigator(s): Jason W. Suh, MD
Status: Open and enrolling
ACCLAIM 1
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer
Principal Investigator(s): Eli Kirshner, MD
Status: Open and enrolling
ASTEFANIA
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Principal Investigator(s): Amanda J. Podolski, MD
Status: Open and enrolling
BPM31510
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Principal Investigator(s): Rupa G. Juthani, MD
Status: Open and enrolling
DRAMMATIC (S1803)
Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Principal Investigator(s): Jason W. Suh, MD
Status: Closed to Enrollment, Patients in Follow-Up
GLORIOSA
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA).
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Open and enrolling